Medical college Froedtert & the Medical College of Wisconsin revealed on Monday that COVID-19 patients in the Southeastern Wisconsin's health network region are being treated with convalescent plasma treatment in the fight against the pandemic.
On 8 April 2020, the company infused its first COVID-19 patient with plasma donated from individuals who have recovered from the virus. There are currently four COVID-19 patients that have been treated with this convalescent plasma treatment. Approved by the FDA as an Emergency Investigational New Drug (EIND), this treatment allows one plasma donation to treat multiple patients and one patient may require more than one plasma transfusion.
The study will reportedly be conducted at up to 90 hospital networks globally and will aim to recruit as many patients as possible. The Froedtert ECMO team has a high level of experience in this advanced therapy and is the only adult ECMO programme in the state designated as a Center on Path to Excellence in Life Support by the Extracorporeal Life Support Organization.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial